Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.

Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.

Oncolytic virotherapy is a novel treatment for cancer that exerts direct lytic and indirect immune-mediated antitumor effects. A Finnish research team has reported on an advanced therapy access program for oncolytic adenovirus. The strengths and weaknesses of this approach are highlighted with a view to informing future study conduct.

Oncolytic viruses are novel immunotherapeutic agents that appear to mediate potent antineoplastic effects in both preclinical and clinical settings. Recent studies demonstrate that manipulating the mechanisms whereby cancer cells die in the course of oncolytic virotherapy has potential to boost anticancer immune responses.

Gene therapy of liver cancer covers a variety of gene transfer strategies aimed to the treatment of patients with primary and secondary liver tumors, including gene directed enzyme/pro-drug therapy, inhibition of oncogenes and restoration of tumor-suppressor genes, immunotherapy, anti-angiogenesis and virotherapy. Some of these strategies have reached early clinical development with diverse lit...

The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider Richard Vile, Dale Ando, and David Kirn Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA; Cell Genesys Corp., Foster City, California, USA; Department of Pharmacology, Oxford University Medical School, Oxford, UK; and Kirn Oncology Consulting, San Francisco, California, ...

objective: in this study, artificial neural network (ann) analysis of virotherapy in preclinical breast cancer was investigated. materials and methods: in this research article, a multilayer feed-forward neural network trained with an error back-propagation algorithm was incorporated in order to develop a predictive model. the input parameters of the model were virus dose, week and tamoxifen ci...